Five lessons for building an external control arm that regulators can use

3 ways to incorporate DE&I in your communications strategy

In this infographic, we outline three ways to incorporate Diversity, Equity and Inclusion into your strategy to deliver inclusive communications that connect with a diverse and multicultural audience

Medical Communications Overview Brochure

Engaging those that matter most

Lessons from China and the United States on the use of RWE in regulatory submissions

Parexel experts have compiled some lessons learned and share recommendations on how companies can be more effective at collecting RWD and generating RWE in different regions

Lessons from China and the United States on the use of RWE in regulatory submissions

Can Synthetic / External Control Arms meet regulatory and HTA requirements?

This article summarizes a recent panel discussion where experts from Parexel and biotech company, MorphoSys, shared their experiences from recent pioneering efforts in RWE.

Strategies for External Control Arms

Multi-stakeholder strategies for external control arms

New ways of thinking are needed about vast sources of data amassed — and how that data can be fit-for-purpose to meet drug approval and access standards.

Guide for Real-World Evidence

Parexel Biotech has created this guide to simplify the nomenclature and types of real-world studies.

Entering a new age of evidence generation: synthetic control models

Expert perspectives from Parexel's Leanne Larson, Senior Vice President and WW Head of Real-World Evidence

Real-world evidence for more efficent, patient-focused trials

Parexel's Amy McKee and Leanne Larson make a case for an evidence-driven approach to drug development.

PharmaVOICE - The RWE Evolution

What the industry is currently experiencing is an evolution of processes founded in solid science and good clinical study practices.

How RWE can help Biotechs optimize the value of their asset

Matthew Gordon, VP of Real-World Evidence Strategy, Parexel, and Jimmy Brown, VP, Parexel Biotech discuss how RWE is a tremendously versatile tool for biotech companies at all stages.